translation agency

NLM AIDSLINE
[Primary prevention of cerebral toxoplasmosis in patients with HIV infection: results of a double-blind randomized trial, pyrimethamine versus placebo]
Morlat P; Chene G; Leport C; Rousseau F; Luft B; Aubertin J; Hafner R;
September 30, 1994
Rev Med Interne. 1993;14(10):1002. Unique Identifier : AIDSLINE

To assess the efficacy of pyrimethamine (Pyr) for primary prophylaxis of cerebral toxoplasmosis (CT) in HIV patients (pts), 554 pts were randomized in a double-blind, placebo-controlled trial (mean follow-up: 14 months). The intent-to-treat analysis found no significant difference in the incidence of ct at 1 year: 12% (Pyr) versus 13% (Pcb) nor in survival. Side-effects leading to stop the study drug were more frequent in Pyr group, especially cutaneous rashes: 8% (Pyr) versus 2% (Pcb).

Double-Blind Method English Abstract Human HIV Infections/*COMPLICATIONS *HIV-1 Placebos Pyrimethamine/*THERAPEUTIC USE Toxoplasmosis, Cerebral/ETIOLOGY/*PREVENTION & CONTROL CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL

www.aegis.org